SCHEMBL1156098

SCHEMBL1156098

CCNS(=O)(=O)Cl

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1111454 0.75
SCHEMBL242031 0.74
SCHEMBL3871336 0.72
SCHEMBL3365101 0.71
SCHEMBL1158769 0.69 PPARA (0.58)
SCHEMBL18195952 0.69 ALDH1A1 (0.34)
SCHEMBL31426 0.69
Diethylamine SCHEMBL27816444 0.69 TP53 (0.57)
SCHEMBL21164876 0.69
SCHEMBL779252 0.69

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 224 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260116881-A1 KIF MODULATOR COMPOUNDS AND METHODS OF USE IAMBIC THERAPEUTICS INC (US) 2026-04-30 US disclosed
EP-4701735-A1 HETEROCYCLIC DERIVATIVE AS MITOGEN-ACTIVATED PROTEIN KINASE (MEK) INHIBITOR Nested Therapeutics, Inc. (US) 2026-03-04 EP disclosed
US-20260001845-A1 MITOGEN-ACTIVATED PROTEIN KINASE (MEK) INHIBITORS NESTED THERAPEUTICS INC (US) 2026-01-01 US disclosed
EP-4634186-A1 2,6,9-TRISUBSTITUTED PURINES Astrazeneca AB (SE) 2025-10-22 EP disclosed
US-12441744-B2 2,6,9-trisubstituted purines ASTRAZENECA AB 2025-10-14 US disclosed
WO-2025202991-A1 CRYSTALLINE FORM OF (S)-N-ETHYL-3-((9-ETHYL-2-(((2R,3S)-2-HYDROXYPENTAN-3-YL)AMINO)-9H-PURIN-6-YL)AMINO)-PYRROLIDINE-1-SULFONAMIDE ASTRAZENECA AB (SE) 2025-10-02 WO disclosed
US-20250288571-A1 MITOGEN-ACTIVATED PROTEIN KINASE (MEK) INHIBITORS NESTED THERAPEUTICS, INC. 2025-09-18 US disclosed
US-20250289811-A1 HETEROCYCLIC DERIVATIVES AS MITOGEN-ACTIVATED PROTEIN KINASE (MEK) INHIBITORS NESTED THERAPEUTICS, INC. 2025-09-18 US disclosed
WO-2025133610-A1 INHIBITORY COMPOUNDS LOQUS23 THERAPEUTICS LIMITED (GB) 2025-06-26 WO disclosed
EP-4574817-A1 INHIBITORY COMPOUNDS LoQus23 Therapeutics Limited (GB) 2025-06-25 EP disclosed
EP-0009054-A1 N-Pyrazinecarbonyl-N'-substituted-sulfamoyl-guanidine and processes for preparing same MERCK & CO. INC. (US) 1980-04-02 EP disclosed
EP-0001266-A1 Substituted 2-aminomethylphenyl sulfamates, process for preparing, and pharmaceutical compositions containing the same MERCK & CO. INC. (US) 1979-04-04 EP disclosed
US-4139700-A ACID-CATALYZED CYCLIZATION OF SULFAMOYL ACID OR ESTER MONSANTO COMPANY (US) 1979-02-13 US disclosed
US-4115573-A N-pyrazinecarbonyl-N'-substituted-sulfamoylguanidine and processes for preparing same MERCK & CO., INC. (US) 1978-09-19 US disclosed
US-4113877-A DIURETICS, ANTIHYPERTENSIVE AGENTS MERCK & CO., INC. (US) 1978-09-12 US disclosed
US-4096181-A Substituted sulfamic acid halides BASF AKTIENGESELLSCHAFT (DT) 1978-06-20 US disclosed
US-4075351-A INHIBITION OF MALE FERTILITY WITH ALIPHATIC SULFAMATES ORTHO PHARMACEUTICAL CORPORATION (US) 1978-02-21 US disclosed
US-4049709-A Vinyl-substituted sulfamic acid halides BASF AKTIENGESELLSCHAFT (DT) 1977-09-20 US disclosed
US-3997585-A Aliphatic sulfamates ORTHO PHARMACEUTICAL CORPORATION (US) 1976-12-14 US disclosed
US-3935201-A Production of 2,1,3-benzothiadiazin-4-one-2,2-dioxides BASF AKTIENGESELLSCHAFT (DT) 1976-01-27 US disclosed